Introduction {#s001}
============

Evidence indicates human milk (HM) feeding in preterm infants, especially in those under 1,500 g (very low birth weight \[VLBW\]), has a lower risk of adverse outcomes compared to feeding these infants wholly or partly cow\'s milk (CM)-based products in terms of necrotizing enterocolitis (NEC),^[@B1]^ late onset sepsis,^[@B5]^ mortality,^[@B7],[@B8]^ retinopathy of prematurity (ROP),^[@B7],[@B9]^ bronchopulmonary dysplasia (BPD),^[@B7],[@B10],[@B12]^ and long-term brain development,^[@B13],[@B14]^ cardiovascular risk,^[@B15]^ bone health,^[@B18]^ atopic disease^[@B19]^ and structural development of the heart, lungs, and great vessels.^[@B20]^ The extent to which these outcomes reflect beneficial effects of HM or conversely adverse effects of CM (or both) is unknown, but regardless of mechanism, such data underpin the strong recommendation to use mother\'s own milk (MOM) for VLBW infants.^[@B21],[@B22]^

When MOM is insufficient, a preterm formula (PTF) has been used. However, the current recommendation of the American Academy of Pediatrics and other groups^[@B21],[@B22]^ is that VLBW infants should, in that case, ideally receive donor milk (DM) rather than PTF providing a 100% HM base diet. This approach requires fortification of the HM to meet nutritional needs of VLBW infants. While many units elect to use HM-derived fortifier (HMDF) as a method of fortification, most currently use of a CM-derived fortifier (CMDF). This practice involves a greater use of HM, the elimination of PTF, but a greater use of CMDF. Yet, the safety aspects of CMDF, in terms of whether there is an increased risk of morbidities as noted above, have been little researched in relationship to this particular feeding guideline.

To address the paucity of evidence on morbidity with this emerging practice, we reanalyzed data from a 12-center clinical trial published in 2010.^[@B1]^ This trial originally compared HM feeding (MOM plus DM, if required, and both fortified with HMDF) to a control group fed MOM fortified with CMDF plus use of preterm infant formula when MOM was insufficient. To replicate the commonly recommended practice, we conducted a subgroup analysis confined to babies whose base diet was 100% MOM and a fortifier was supplemental to this, allowing comparison of CMDF versus HMDF in otherwise entirely MOM-fed babies. Our primary hypothesis was that when used in this situation, CMDF would adversely impact the incidence of NEC, NEC surgery and/or death.

Materials and Methods {#s002}
=====================

Relevant aspects of the original trial {#s003}
--------------------------------------

Infants were recruited from 12 neonatal units, 11 in the United States and one in Austria. Eligibility criteria included birth weight between 500 and 1,250 g, mother\'s intention to provide her milk, and initiation of enteral feeding before 21 days and parenteral nutrition within 48 hours after birth. Exclusions included major malformations or likely transfer to nonstudy institutions. This trial used block, stratified (by birthweight and small for gestational age \[SGA\] status) randomization and described previously.^[@B1]^ The study was approved by the Institutional Review Boards of each center, and written informed consent was obtained from the parents or legal guardians of all subjects before enrollment. The original trial was registered with [Clinicaltrials.gov](Clinicaltrials.gov) reg. \#NCT00506584.

All study infants received MOM and were randomized to fortifier type received and type of milk used if MOM was insufficient. Two exclusively HM-fed groups, HM100 and HM40, received pasteurized donor HMDF (Prolact+H2MF; Prolacta Bioscience, City of Industry, California) when the enteral intake was 100 and 40 mL/\[kg·day\], respectively, and both groups received pasteurized and standardized 20 kcal/oz donor HM if MOM was not available in sufficient quantity. The CM control group received CMDF when the enteral intake was 100 mL/\[kg·day\] and PTF if MOM was not available in sufficient quantity.

Study duration was the earliest of the following: 91 days of age, discharge from hospital, or attainment of 50% oral feedings. Trophic feedings were initiated 1--4 days postnatally and continued at 10--20 mL/\[kg·day\] as tolerated for up to 5 days. Subsequently, milk intake was increased by 10--20 mL/\[kg·day\]. HMDF was added at 40 or 100 mL/\[kg·day\]; the HM40 group tested a further hypothesis that HMDF could safely be used earlier than the conventional time of introduction of a fortifier. CMDF (Enfamil HMF; Mead Johnson, Evansville, IN; or Similac HMF; Abbott Laboratories, Columbus, OH) was added in the CM group when enteral intake reached 100 mL/\[kg·day\]. After starting fortification, milk intake was increased daily by 10--20 mL/kg to a maximum of 160 mL/\[kg·day\]. Nutritional content of the study diet was described previously.^[@B1]^

NEC was defined as Bell stage II disease or greater. Abdominal radiographs were read by radiologists unaware of study group assignment, regardless of the suspicion of NEC. All suspected and actual cases were adjudicated by a panel of neonatologists, also unaware of the study group assignment, before confirming the clinical diagnosis.^[@B23]^ After the study, all cases of NEC were reviewed in a blinded manner by a panel of eight of the study investigators. The original diagnosis of NEC was used for this current subgroup analysis.

Daily body weight and weekly recumbent length and head circumference were recorded. BPD was defined as use of supplemental oxygen at 36 weeks postmenstrual age (PMA); late-onset sepsis as clinical signs and symptoms consistent with sepsis occurring more than 5 days after birth with the isolation of a causative organism from a blood culture^[@B24]^ (on at least two occasions for coagulase-negative staphylococcus).

Current trial subgroup reanalysis {#s004}
---------------------------------

Subgroup analysis was performed using data from those infants for whom MOM was 100% of base diet prefortification; so, the only difference between groups was whether CMDF or HMDF was used.

In the original trial, the HM40 and HM100 groups were merged, since the outcomes were the same. Merging was maintained for the current analysis after confirming no difference between these two HMDF groups in baseline characteristics or outcomes. This merging explains why the HMDF group had 82 subjects versus 32 in the CMDF group.

Choice of outcomes for the current reanalysis {#s005}
---------------------------------------------

The main outcome for the current study was NEC (Bells\' stage II or greater)---a predetermined outcome of the original trial. Our further main outcome, a severe morbidity index of NEC surgery or death, also derived from the findings of the original trial (Clinical Trials NCT00506584), in which NEC surgery was a major outcome, analyzed separately; and because of the high risk of immediate or later death in those requiring surgery, death is logically included since it has a censoring effect on the incidence of NEC surgery. When the original trial was analyzed jointly with the sister trial,^[@B2]^ there was a significant fourfold increased risk of all-cause death rate in the CM versus HM group (8% versus 2%).^[@B8]^ Also, analyzing NEC surgery or death as a combined index added power to this subgroup analysis given the smaller sample than in the original trial.

The secondary clinical outcomes included further morbidities where a higher incidence had been linked to CM exposure in other publications: BPD,^[@B7],[@B10]^ requirement for mechanical ventilation,^[@B7]^ ROP,^[@B7],[@B9]^ and sepsis.^[@B5]^ We also recorded growth.

Statistical analysis {#s006}
--------------------

The baseline comparisons of categorical data used the chi-square test for homogeneity or Fisher\'s exact test^[@B25]^ for small cell sizes. Comparisons of baseline quantitative variables used the two-sample *t*-test. The unadjusted comparison of the rates of the different outcomes was based on the use of Fisher\'s exact test, while adjusted comparisons based on clinically relevant covariates utilized dichotomous logistic regression.^[@B26]^ Comparison of quantitative outcomes also used the Wilcoxon rank sum test.

Results {#s007}
=======

Over 14 months, 334 infants were screened, and 207 enrolled in the original trial; and 114 were selected for this subgroup analysis ([Fig. 1](#f1){ref-type="fig"}).

![CONSORT diagram---distribution of study subjects. CM, group exposed to cow\'s milk-derived feeds (preterm formula or fortifier); CMDF, group fed cow\'s milk-derived fortifier; HM, group fed all human milk (HM100 or HM40); HM40, group fed human milk-derived fortifier with fortification starting at feed volume 40 mL/kg; HM100, group fed human milk-derived fortifier with fortification starting at feed volume 100 mL/kg; HMDF, group fed human milk-derived fortifier; MOM, mother\'s own milk.](bfm.2019.0133_figure1){#f1}

Baseline demographic factors were not significantly different between CMDF versus HMDF groups ([Table 1](#tb1){ref-type="table"}), nor between this and the original study (not illustrated).

###### 

Baseline Characteristics Comparing Infants Fed a Human Milk-Derived Fortifier Versus Cow\'s Milk-Derived Fortifier

  Parameter            HMDF (*n* = 82)   CMDF (*n* = 32)   p^[a](#tf1){ref-type="table-fn"}^
  -------------------- ----------------- ----------------- -----------------------------------
  Sex (female)         47/82 (57.3%)     15/32 (46.9%)     0.31
  Race (black)         16/82 (19.5%)     3/32 (9.4%)       0.19
  Antenatal steroids   67/82 (81.7%)     26/32 (81.2%)     0.95
  APGAR \<7            8/82 (9.8%)       6/32 (18.8%)      0.19
  Gestation (weeks)    27.3 ± 2.2        27.1 ± 1.8        0.63
  Birthweight (g)      937 ± 199         938 ± 190         0.98
  SGA at birth         10/82 (12.2%)     3/32 (9.4%)       0.67

*t*-Test for quantitative variables and chi-square/Fisher\'s exact test for categorical variables.

CMDF, cow\'s milk-derived fortifier; HMDF, human milk-derived fortifier; SGA, small for gestational age.

The total hospitalization dose (intake) of MOM was equivalent in the two groups: 7.1 ± 3.8 L in the CMDF group and 6.8 ± 3.7 L in the HMDF group (*p* = 0.71). However, the proportion of MOM seen in this reanalysis (and in the original trial) was lower with HMDF versus CMDF (0.80 ± 0.09 versus 0.97 ± 0.01): entirely due to the liquid nature of the HMDF versus the powdered CMDF.

Fortifier was introduced earlier in the HMDF versus CMDF group: median 14.0 days versus 16.5 days (*p* = 0.03).

Study outcomes {#s008}
--------------

The incidence of Bell\'s stage II or greater NEC ([Table 2](#tb2){ref-type="table"})^[@B23]^ was significantly higher in the CMDF group 5/32 cases versus 3/82 cases---a relative risk (RR) of 4.2 (*p* = 0.038). After adjusting for race and Apgar score---the two baseline characteristics most different between groups (although not significantly so), the group difference was even more significant (*p* = 0.018).

###### 

Primary and Secondary Outcomes Comparing Infants Fed a Human Milk-Derived Fortifier Versus Cow\'s-Milk Derived Fortifier

  Parameter                                              HMDF (*n* = 82)   CMDF (*n* = 32)   p^[a](#tf3){ref-type="table-fn"}^
  ------------------------------------------------------ ----------------- ----------------- -----------------------------------
  NEC (Bell Stage 2 or greater)                          3/82 (3.7%)       5/32 (15.6%)      0.038
  NEC surgery or death^[b](#tf4){ref-type="table-fn"}^   3/82 (3.7%)       6/32 (18.8%)      0.014
  Surgical NEC^[b](#tf4){ref-type="table-fn"}^           1/82 (1.2%)       3/32 (9.4%)       0.066
  Death^[b](#tf4){ref-type="table-fn"}^                  3/82 (3.7%)       4/32 (12.5%)      0.096
  BPD                                                    24/82 (29.3%)     11/32 (34.4%)     0.60
  Ventilator days                                        Median 9.5        Median 15.5       0.56
  IQR = 0.75, 41.25                                      IQR = 1, 50.25                      
  ROP (grade 3 or 4)                                     6/82 (7.3%)       2/32 (6.3%)       1.0

Chi-square/Fisher\'s exact test for categorical variables; for ventilator days, Wilcoxon\'s test.

Note that for the index "NEC surgery or death" there are three versus six cases in the HMDF and CMDF groups; this is one less in each group than the sum of NEC surgery and death when shown individually. This is because in each diet group, one case had *both* NEC surgery and death (not counted twice in the index).

BPD, bronchopulmonary dysplasia; CMDF, cow\'s milk-derived fortifier; HMDF, human milk-derived fortifier; ROP, retinopathy of prematurity.

For the severe morbidity index of NEC surgery or death ([Table 2](#tb2){ref-type="table"}), 6/32 (18.8%) subjects in the CMDF group had a positive index compared to 3/82 (3.7%) in the HMDF group; an RR of 5.1 (*p* = 0.014). The number of subjects needed to harm was 7 (6.6). Thus, each seven infants treated with CMDF was associated with a death or case of NEC surgery.

Exploratory analyses {#s009}
--------------------

In an exploratory analysis we took account of one protocol violator in the HMDF group (none in the CMDF group). This sole violator was the only subject that had NEC surgery in the HMDF group and hence had some influence. For the exploratory analysis, fortifier type and NEC, transferring the violator from the HMDF to the CMDF group changed the split of NEC cases to 6/32 (18.8) in the CMDF group versus 2/82 (2.4%) in the HMDF group; an RR of 7.8 (*p* = 0.008). For the severe morbidity index, the corresponding split became 7/32 (21.9%) in the CMDF group versus 2/82 (2.4%); RR = 9.1 (*p* = 0.002).

The incidence of NEC surgery and death in the two groups are shown separately (not combined as an index) as secondary outcomes in [Table 2](#tb2){ref-type="table"}. All 7 deaths occurred between day 8 and 53 and were related to NEC or sepsis.

Growth-related outcomes {#s010}
-----------------------

[Table 3](#tb3){ref-type="table"} shows no difference in days to regain birth weight or in the rate of weight gain or length gain between the CMDF and HMDF groups. However, head circumference gain, reflecting brain growth, was 13% higher in the HMDF group; median 0.78 cm/week compared to 0.68 cm/week in the CMDF group (*p* = 0.04). None of the other outcomes was different between groups.

###### 

Growth Characteristics of Infants Fed a Human Milk- Derived Fortifier Versus Cow\'s Milk-Derived Fortifier

  Parameter                    HMDF (*n* = 82)                    CMDF (*n* = 32)                    p^[a](#tf6){ref-type="table-fn"}^
  ---------------------------- ---------------------------------- ---------------------------------- -----------------------------------
  Days to regain birthweight   Median = 6.5 (IQR = 3, 10)         Median = 6.0 (IQR = 2, 9)          0.24
  Weight (g/\[kg·day\])        Median = 14.5 (IQR = 13.0, 15.9)   Median = 14.6 (IQR = 12.4, 16.2)   0.90
  Length (cm/week)             Median = 0.90 (IQR = 0.68, 1.08)   Median = 0.88 (IQR = 0.63, 1.14)   0.58
  HC (cm/week)                 Median = 0.78 (IQR = 0.63, 0.88)   Median = 0.68 (IQR = 0.59, 0.80    0.04

Wilcoxon test.

CMDF, cow\'s milk-derived fortifier; HD, head circumference; HMDF, human milk-derived fortifier; IOR, interquartile range.

Discussion {#s011}
==========

A rapidly emerging target in neonatal care, backed by official guidelines,^[@B21],[@B22]^ is to feed small preterm infants a HM diet based on MOM and, if required, DM. Current common practice is to fortify these with a CMDF. Despite the increasing prevalence of this practice, safety aspects in comparison with HMDF have been minimally studied. Thus, while the use of CM-based products is linked to increased risk of a major morbidity,^[@B1]^ remarkably few data apply where fortifiers are used as the sole source of CM.

The development of HMDF^[@B1],[@B2]^ has created the opportunity for randomized and nonrandomized controlled studies that could compare any morbidity associated with CMDF (when used as the sole source of CM) against HMDF as a non-CM-based comparison group; and where both groups received a base diet of HM. Despite the high intake of MOM, CMDF was still associated with a more than fourfold increased RR of NEC and over fivefold increased risk of severe morbidity comprising NEC surgery or death. While death itself is a major adverse outcome, it is important to include this in studies of NEC because of the censoring effect caused by death of babies who would otherwise be at higher risk of NEC had they survived. NEC cases requiring surgery have the worst prognosis for postneonatal complications, later death and adverse neurodevelopmental outcome. Thus, strategies to reduce NEC have major importance for the survival and quality of life of VLBW infants.

Two further studies add weight to our findings. The recently published OptiMoM trial^[@B9]^ in VLBW infants had an appropriate design to address safety of CMDF with modern practice. With a base diet of 100% HM (MOM and when required, DM), subjects were randomized to CMDF or HMDF. Severe ROP, was significantly more common in the CMDF group, in concordance with other studies on CM versus HM.^[@B7],[@B9]^ There was a trend toward more late onset sepsis in the CMDF group (80% increase *p* = 0.07). These authors predefined a dichotomous morbidity index of death, NEC, ROP, BPD, or sepsis and following a recent published corrigendum the data showed a trend to a higher risk of a positive morbidity index in the CMDF group (40% higher, *p* = 0.07).^[@B27]^ Thus, as in our own study, there were safety concerns relating to CMDF.

Second, the RCT of Lucas et al.^[@B28]^ involved 276 preterm infants fed a base diet of MOM with PTF if required. Although the base diet was not 100% MOM, the study had the advantage of being conducted when CMDFs were introduced, ethically permitting randomisation to CMDF or to no fortification. The trial showed that the addition of CMDF to breast milk as the sole intervention more than doubled the combined incidence of confirmed NEC or proven sepsis compared to the no-treatment limb.

While others have shown CM exposure increased risk of ROP and sepsis, we did not show that here.^[@B5]^ This may be due to the high use of MOM in both limbs (100% of base diet). Also, RR of these outcomes with CM, as shown in other studies, is not as high as for NEC, necessitating a larger sample.

Those fed with CMDF and HMDF had similar growth in weight and length; and the median weight gain was 14.5 and 14.6 g/\[kg·day\], respectively. These latter figures reflect lower rates of growth than currently targeted, but are nevertheless close to the mean weight gain of 14.6 g/\[kg·day\] from 1 week postnatally to 34 weeks PMA in infants born at 27.6 weeks gestation in the Preterm Multi-Center Growth Study.^[@B29]^ However, the CMDF group had a moderate 13% lower rate in head circumference gain, and hence reduced brain growth, compared with the HMDF group. This requires investigation in further studies. One hypothesis explains that this is the high concentration of HM fat in the HMDF that could supply HM fat globule membrane^[@B30]^ or component lipids such as sphingomyelin that could promote white matter formation and cognitive development.^[@B31]^

We speculate the adverse effects of CMDF, despite a 100% HM base diet, could relate to the unexpectedly high dose of CM protein derived from fortifier, around 50% of protein intake. A current hypothesis is that CM may cause dysbiosis of the microbiome that precedes NEC and may be part of the causal sequence,^[@B32]^ although there is a paucity of evidence on whether there is any differential impact of PTF versus CMDF on the microbiome. A further potential factor is that when CM is directly added to MOM, it may diminish its protective properties.^[@B33]^

Limitations {#s012}
-----------

Our subgroup analysis could have created imbalances between the groups. However, the groups were well balanced for demographic factors and adjusting for race and Apgar score actually increased the significance of the association of CMDF with NEC. The greater morbidity in the CMDF group could potentially reflect an underlying higher risk population rather than a causal adverse effect of CMDF. We suggest the evidence points strongly against that. Our hypothesis was an a priori one driven by key outcomes in the original trial. Baseline risk factors were well balanced between groups. A large body of evidence links CM exposure to risk of NEC; and the effect size was large.

The CMDF subgroup had only 32 subjects who fulfilled our selection criteria. While this might have raised concern over the potential for type II error, this was not relevant here since the hypothesized dietary effect was significant; and a type I error is controlled by the significance level used (5%).

As noted, our study findings apply to the situation where the base diet is all MOM as data from DM studies were not specifically analyzed.

Our original trial population, although comprising very small infants, had a higher NEC rate than commonly seen today. Nevertheless, our findings that NEC was not reduced with sole use of CMDF as the CM source and that NEC rates were higher with CMDF versus HMDF remain the key observations in our study.

Finally, our findings apply to intact protein fortifiers in widespread international use. We did not consider here partially or extensively hydrolyzed fortifiers, now used in the United States. Such fortifiers have been compared with each other with some differences,^[@B34]^ but not compared to HMDF for the broad range of morbidities differentially affected by CM versus HM exposure.

Conclusion {#s013}
==========

In a subgroup analysis of a RCT, we have used the opportunity to study the safety of CMDF compared to HMDF in VLBW premature babies fed a base diet of all MOM. Our findings showed adverse effects of using CMDF compared to HMDF with a 4.2-fold increased risk of NEC and a 5.1-fold increased risk of NEC surgery or death. Thus, those fed a HMDF were significantly advantaged in terms of a reduced incidence of morbidity. These data may help to underpin future strategies for quality improvement in neonatal nutrition.
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